PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Urology

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.juro.2010.06.098PMID 20850153
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.

  2008cited by this paper
• PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

  2008cited by this paper
• PCA3: a molecular urine assay for predicting prostate biopsy outcome.

  2008cited by this paper
• A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy.

  2008cited by this paper
• PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.

  2008cited by this paper
• PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

  2007cited by this paper
• APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

  2006cited by this paper
• Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.

  2004cited by this paper
• DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

  2003cited by this paper
• DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer

  2003cited by this paper
• DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.

  2002cited by this paper
• DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

  1999cited by this paper
• Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

  1988cited by this paper
• Aptima Pca3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer

  year unknowncited by this paper

• The Impact of Urine Biomarkers for Prostate Cancer detection - A Systematic State of the Art Review.

  2025cites this paper
• Clinical significance of urine-based automated detection of GSTP1 methylation for the diagnosis of suspected prostate cancer patients

  2025influential citation
• Genetic associations of prostate cancer in China: a systematic review

  2025cites this paper
• Measurement of PDE5 concentration in human serum: proof-of-concept and validation of methodology in control and prostate cancer patients

  2024influential citation
• Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination

  2023cites this paper
• UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging.

  2022cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Prostate Cancer Early Detection Version 1 . 2022 —

  2022cites this paper
• Long noncoding RNA as a potential diagnostic tool for prostate cancer: a systematic review and meta-analysis

  2022cites this paper
• A review on the role of PCA3 lncRNA in carcinogenesis with an especial focus on prostate cancer.

  2022cites this paper
• PCA3 in Prostate Cancer.

  2021cites this paper
• Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis

  2021cites this paper
• Initial experience with SelectMDx® in the diagnosis of prostate cancer in a real-world evidence clinical practice setting

  2020cites this paper
• Diagnosis of prostate cancer: the implications and proper utilization of PSA and its variants; indications and use of MRI and biomarkers.

  2020cites this paper
• Affinity Captured Urinary Extracellular Vesicles Provide mRNA and miRNA Biomarkers for Improved Accuracy of Prostate Cancer Detection: A Pilot Study

  2020cites this paper
• Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer

  2020cites this paper
• Narrative review of urinary glycan biomarkers in prostate cancer

  2020cites this paper
• Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis.

  2020cites this paper
• Initial experience with SelectMDx® in the diagnosis of prostate cancer in a real-world evidence clinical practice setting.

  2020cites this paper
• The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer

  2019cites this paper
• Prostate Cancer Biomarkers in Proximal Fluids

  2019cites this paper
• The Prospect and Challenges to the Flow of Liquid Biopsy in Africa

  2019cites this paper
• Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis

  2019influential citation
• Chapter 2 Biomarkers for Diagnosis and Prognosis of Prostate Cancer

  2019cites this paper
• Novel Diagnostic Biomarkers of Prostate Cancer: An Update.

  2019cites this paper
• A critical appraisal of biomarkers in prostate cancer

  2019cites this paper
• Biomarkers for Diagnosis and Prognosis of Prostate Cancer

  2018cites this paper
• PCA3 rs544190G>A and prostate cancer risk in an eastern Chinese population

  2018cites this paper
• Utilizing Biomarkers in Patients with Prior Negative Prostate Biopsy

  2018cites this paper
• Molecular strategies to reduce unnecessary repeat prostate biopsies of men with elevated serum PSA

  2018cites this paper
• Renal

  2018cites this paper
• [What primary care physicians should know about new markers in prostate cancer].

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Urinary biomarkers of prostate cancer

  2018cites this paper
• Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low‐risk prostate cancer receiving 5α‐reductase inhibitors

  2018cites this paper
• Genetic signatures on prostate biopsy: clinical implications

  2018cites this paper
• Longitudinal Assessment of Urinary PCA3 for Predicting Prostate Cancer Grade Reclassification in Favorable Risk Men during Active Surveillance

  2017cites this paper
• Editorial Comment to Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma

  2017cites this paper
• Canadian Urological Association recommendations on prostate cancer screening and early diagnosis

  2017cites this paper
• The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice

  2017cites this paper
• Prostate Cancer: An Update on Molecular Pathology with Clinical Implications

  2017cites this paper
• Novel biomarkers for prostate cancer: An evidence‐based review for use in clinical practice

  2017cites this paper
• Urological Association recommendations on prostate cancer screening and early diagnosis

  2017cites this paper
• Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.

  2017cites this paper
• The role of prostate cancer biomarkers in undiagnosed men

  2017cites this paper
• Outcomes of expanded use of PCA 3 testing in a Spanish population with clinical suspicion of prostate cancer

  2017cites this paper
• Recommandations de l'Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate.

  2017cites this paper
• Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis.

  2017cites this paper
• The Use of Biomarkers in Prostate Cancer Screening and Treatment.

  2017cites this paper
• Management of men with previous negative prostate biopsy

  2016cites this paper
• Chapter 53 – Prostate Cancer

  2016cites this paper
• Clinical Considerations after a Negative Prostate Biopsy

  2016cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Prostate Cancer Early Detection

  2016cites this paper
• Urinary Biomarkers for Prostate Cancer.

  2016cites this paper
• How Precisely Can Prostate Cancer Be Managed?

  2016cites this paper
• Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis

  2016cites this paper
• Comprehensive assessment for novel prostate cancer markers in the prostate‐specific antigen era: Focusing on Asians and Asian countries

  2015cites this paper
• Prostate Cancer Early Detection, Version 2.2015

  2015cites this paper
• Addressing the need for repeat prostate biopsy: new technology and approaches

  2015cites this paper
• Prostate Cancer Early Detection Panel Members

  2015cites this paper
• Current biomarkers for diagnosing of prostate cancer.

  2015cites this paper
• Molecular Updates in Prostate Cancer.

  2015cites this paper
• RNA biomarkers to facilitate the identification of aggressive prostate cancer.

  2015cites this paper
• Assessment of long‐term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy

  2015cites this paper
• In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12‐core biopsy still necessary in addition to a targeted biopsy?

  2015cites this paper
• NCCN Guidelines Version 2 . 2017 Table of Contents Prostate Cancer Early Detection

  2015cites this paper
• The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.

  2015influential citation
• Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.

  2015cites this paper
• EN2 in Prostate Cancer.

  2015cites this paper
• Neue Biomarker im Serum und im Urin zur Detektion des Prostatakarzinoms

  2015cites this paper
• The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer.

  2015cites this paper
• Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy.

  2014cites this paper
• Role of β-microseminoprotein from prostate cancer initiation to recurrence: A mini-review

  2014cites this paper
• Quantitative Analysis of Novel Prostate Cancer Markers in Tissue

  2014cites this paper
• Biomarcadores en el cáncer de próstata. Implicación en la práctica clínica

  2014cites this paper
• A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer

  2014cites this paper
• The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis

  2014cites this paper
• Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis

  2014cites this paper
• РСА3 - истинный онкомаркер рака предстательной железы (обзор литературы)

  2014cites this paper
• Le test urinaire PCA3 : quelles perspectives ?

  2014cites this paper
• Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.

  2014cites this paper
• Prostate-specific antigen and other serum and urine markers in prostate cancer.

  2014cites this paper
• Biopsy sampling and histopathological markers for diagnosis of prostate cancer

  2014cites this paper
• PCA3 score of 20 could improve prostate cancer detection: results obtained on 734 Italian individuals.

  2014cites this paper
• EPS Biomarkers Improve Stratification of NCCN Active Surveillance Candidates: Performance of Secretion Capacity and TMPRSS2:ERG Models

  2014cites this paper
• Reflex PCA3 messenger ribonucleic acid testing: validation of postbiopsy urine samples and correlation with prostate biopsy findings in ∼2000 patients.

  2014cites this paper
• Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis

  2013cites this paper
• Prostate Cancer Screening: Navigating the Controversy

  2013cites this paper
• Biopsy and radical prostatectomy pathological patterns influence Prostate cancer gene 3 (PCA3) score.

  2013cites this paper
• 1 Comparative Effectiveness Review Number 98 PCA 3 Testing for the Diagnosis and Management of Prostate Cancer Executive

  2013cites this paper
• PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples.

  2013cites this paper
• Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk‐associated SNPs

  2013cites this paper
• PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.

  2013cites this paper
• Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?

  2013cites this paper
• PCA3 in the detection and management of early prostate cancer

  2013cites this paper
• Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in France

  2013cites this paper
• Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?

  2013cites this paper
• Early detection, PSA screening, and management of overdiagnosis.

  2013cites this paper
• The end of the road for prostate specific antigen testing?

  2013cites this paper
• Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy

  2013cites this paper
• PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.

  2013cites this paper